Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

MIRODERM H2H DFU Study
Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
A Step Ahead Foot Care
mi
from
Mount Vernon, NY
MIRODERM H2H DFU Study
Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
A Step Ahead Foot Care
mi
from
Mount Vernon, NY
Click here to add this to my saved trials
MIRODERM H2H DFU Study
Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
Gramercy Park Podiatry
mi
from
New York, NY
MIRODERM H2H DFU Study
Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
Gramercy Park Podiatry
mi
from
New York, NY
Click here to add this to my saved trials
MIRODERM H2H DFU Study
Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
Foot Associates of New York
mi
from
New York, NY
MIRODERM H2H DFU Study
Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
Foot Associates of New York
mi
from
New York, NY
Click here to add this to my saved trials
MIRODERM H2H DFU Study
Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
Foot and Ankle Institute
mi
from
Saint George, UT
MIRODERM H2H DFU Study
Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
Foot and Ankle Institute
mi
from
Saint George, UT
Click here to add this to my saved trials
MIRODERM H2H DFU Study
Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
ILD Research
mi
from
Carlsbad, CA
MIRODERM H2H DFU Study
Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
ILD Research
mi
from
Carlsbad, CA
Click here to add this to my saved trials
MIRODERM H2H DFU Study
Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
Kansas City Institute of Podiatry
mi
from
Overland Park, KA
MIRODERM H2H DFU Study
Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
Kansas City Institute of Podiatry
mi
from
Overland Park, KA
Click here to add this to my saved trials
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
East Valley Foot & Ankle Specialists
mi
from
Mesa, AZ
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
East Valley Foot & Ankle Specialists
mi
from
Mesa, AZ
Click here to add this to my saved trials
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
Center for Clinical Research Inc.; i
mi
from
San Francisco, CA
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
Center for Clinical Research Inc.; i
mi
from
San Francisco, CA
Click here to add this to my saved trials
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
Animas Foot and Ankle
mi
from
Durango, CO
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
Animas Foot and Ankle
mi
from
Durango, CO
Click here to add this to my saved trials
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
GF Professional Research Group Corporation
mi
from
Miami Lakes, FL
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
GF Professional Research Group Corporation
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
Podiatry 1st
mi
from
Belleville, IL
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
Podiatry 1st
mi
from
Belleville, IL
Click here to add this to my saved trials
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
Clinical Research Associates of Central PA
mi
from
Altoona, PA
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
Clinical Research Associates of Central PA
mi
from
Altoona, PA
Click here to add this to my saved trials
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
Futuro Clinical Trials, LLC
mi
from
McAllen, TX
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
Futuro Clinical Trials, LLC
mi
from
McAllen, TX
Click here to add this to my saved trials
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
Endeavor Clinical Trials, PA
mi
from
San Antonio, TX
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
Endeavor Clinical Trials, PA
mi
from
San Antonio, TX
Click here to add this to my saved trials
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
1Foot 2Foot Centre for Foot & Ankle Care PC
mi
from
Suffolk, VA
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
1Foot 2Foot Centre for Foot & Ankle Care PC
mi
from
Suffolk, VA
Click here to add this to my saved trials
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
Aalborg Universitetshospital
mi
from
Aalborg,
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
Aalborg Universitetshospital
mi
from
Aalborg,
Click here to add this to my saved trials
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated:  12/31/1969
Steven M. Waldman, SC
mi
from
Wauwatosa, WI
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers
A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers
Status: Enrolling
Updated: 12/31/1969
Steven M. Waldman, SC
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Anaheim, CA
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Miami Lakes, FL
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Miami, FL
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Baton Rouge, LA
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
New York, NY
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Orlando, FL
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Berlin, NJ
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Berlin, NJ
Click here to add this to my saved trials
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Merthyr Tydfil,
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Merthyr Tydfil,
Click here to add this to my saved trials
Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology
Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Stanford, CA
Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology
Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Joslin Diabetes Center
mi
from
Boston, MA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Joslin Diabetes Center
mi
from
Boston, MA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retinal Diagnostic Center
mi
from
Campbell, CA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retinal Diagnostic Center
mi
from
Campbell, CA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Atlantis Eye Care
mi
from
Huntington Beach, CA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Atlantis Eye Care
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Northern California Retina Vitreous Associates
mi
from
Mountain View, CA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Northern California Retina Vitreous Associates
mi
from
Mountain View, CA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retinal Consultants of Southern California Medical Group, Inc.
mi
from
Westlake Village, CA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retinal Consultants of Southern California Medical Group, Inc.
mi
from
Westlake Village, CA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
National Ophthalmic Research Institute
mi
from
Fort Myers, FL
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
National Ophthalmic Research Institute
mi
from
Fort Myers, FL
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Florida Retina Consultants
mi
from
Lakeland, FL
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Florida Retina Consultants
mi
from
Lakeland, FL
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Southeast Eye Institute, P.A. dba Eye Associates of Pinellas
mi
from
Pinellas Park, FL
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Southeast Eye Institute, P.A. dba Eye Associates of Pinellas
mi
from
Pinellas Park, FL
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Sarasota Retina Institute
mi
from
Sarasota, FL
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Sarasota Retina Institute
mi
from
Sarasota, FL
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Southeast Retina Center, P.C.
mi
from
Augusta, GA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Southeast Retina Center, P.C.
mi
from
Augusta, GA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Thomas Eye Group
mi
from
Sandy Springs, GA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Thomas Eye Group
mi
from
Sandy Springs, GA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
John-Kenyon American Eye Institute
mi
from
New Albany, IN
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
John-Kenyon American Eye Institute
mi
from
New Albany, IN
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Wolfe Eye Clinic
mi
from
West Des Moines, IA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Wolfe Eye Clinic
mi
from
West Des Moines, IA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Mid-America Retina Consultants, P.A.
mi
from
Overland Park, KA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Mid-America Retina Consultants, P.A.
mi
from
Overland Park, KA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retina and Vitreous Associates of Kentucky
mi
from
Lexington, KY
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retina and Vitreous Associates of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Elman Retina Group, PA
mi
from
Baltimore, MD
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Elman Retina Group, PA
mi
from
Baltimore, MD
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Valley Eye Physicians & Surgeons
mi
from
Ayer, MA
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Valley Eye Physicians & Surgeons
mi
from
Ayer, MA
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Vitreo-Retinal Associates
mi
from
Grand Rapids, MI
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Vitreo-Retinal Associates
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
The Retina Institute
mi
from
Saint Louis, MO
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
The Retina Institute
mi
from
Saint Louis, MO
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Charlotte Eye Ear Nose and Throat Assoc, PA
mi
from
Charlotte, NC
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Charlotte Eye Ear Nose and Throat Assoc, PA
mi
from
Charlotte, NC
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retina Vitreous Center
mi
from
Edmond, OK
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retina Vitreous Center
mi
from
Edmond, OK
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Southeastern Retina Associates, P.C.
mi
from
Knoxville, TN
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Southeastern Retina Associates, P.C.
mi
from
Knoxville, TN
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retina Research Center
mi
from
Austin, TX
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retina Research Center
mi
from
Austin, TX
Click here to add this to my saved trials
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated:  12/31/1969
Retina Center of Texas
mi
from
Grapevine, TX
PROMINENT-Eye Ancillary Study (Protocol AD)
PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)
Status: Enrolling
Updated: 12/31/1969
Retina Center of Texas
mi
from
Grapevine, TX
Click here to add this to my saved trials